ライフサイエンスコーパス: aspartate transaminase

1 age histologically and by elevation of serum aspartate transaminase.

2 ive hepatocyte damage and elevation of serum aspartate transaminase.

3 levated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%-16.5%) and a

4 ; reference range, 0-20 mm/h), and increased aspartate transaminase (38 U/L [0.63 mukat/L]; reference

5 ; reference range, 0-20 mm/h), and increased aspartate transaminase (38 U/L [0.63 mukat/L]; reference

6 Serum aspartate transaminase (70% vs. 31%, P =.04) and alkalin

7 lated malate dehydrogenase activity, but not aspartate transaminase activity, in HFD-fed mice.

8 Median peak aspartate transaminase after transplantation was 925 (in

9 LD activity score, steatosis, triglycerides, aspartate transaminase, alanine transaminase, and stella

10 tinine and blood urea nitrogen) and hepatic (aspartate transaminase, alanine transaminase, and total

11 significant increases in the serum levels of aspartate transaminase, alanine transaminase, blood urea

12 (P =.002), diabetes mellitus (P =.009), and aspartate transaminase/alanine transaminase (AST/ALT) ra

13 ase level greater than 30 U/L, and (3) serum aspartate transaminase/alanine transaminase level less t

14 After OLT, the mean peak aspartate transaminase and alanine transaminase concentr

15 There were decreases in aspartate transaminase and alanine transaminase in the a

16 Majority preferred aspartate transaminase and alanine transaminase less tha

17 lesterol, uric acid, and the hepatic enzymes aspartate transaminase and alanine transaminase were sig

18 al (creatinine and cystatin-C), and hepatic (aspartate transaminase and alanine transaminase) damage

19 ade 3 laboratory toxicity (>10%) included an aspartate transaminase and gamma-glutamyltransferase inc

20 in BCAT1 activity, but also by reductions in aspartate transaminase and glutamate dehydrogenase activ

21 ng had significantly reduced levels of serum aspartate transaminase and tumor necrosis factor-alpha,

22 rved in serum aminotransferases (alanine and aspartate transaminases) and lactate dehydrogenase level

23 alkaline phosphatase, alanine transaminase, aspartate transaminase, and bile acids.

24 with other renal injury markers (creatinine, aspartate transaminase, and heart-type fatty acid bindin

25 lower peak serum alanine transaminase (ALT), aspartate transaminase, and higher peak serum alkaline p

26 acebo, levels of gamma-glutamyl transferase, aspartate transaminase, and soluble tumor necrosis facto

27 of apoptotic hepatocytes, serum alanine and aspartate transaminases, and DNA fragments in the cytoso

28 ignificant difference in peak serum alanine, aspartate transaminases, and lactate dehydrogenase after

29 In this network, we identified aspartate transaminase AspC as a major connector between

30 040), aspartate transaminase (AST) (135.5 +/- 52.3 to 56.3 +/-

31 lirubin (0.9 +/- 0.1 vs. 1 +/- 0.1, P =.07), aspartate transaminase (AST) (58 +/- 5 vs. 56 +/- 6, P =

32 ambs, which were accompanied by elevation of aspartate transaminase (AST) (P <.01).

33 Concomitantly, serum aspartate transaminase (AST) activity was significantly

34 (-/-) mice manifested as profoundly elevated aspartate transaminase (AST) and alanine transaminase (A

35 ated by using a model enzyme pair comprising aspartate transaminase (AST) and malic dehydrogenase.

36 ALT) decreased by 59.6% (P<0.05) and that of aspartate transaminase (AST) decreased by 75.4% (P<0.05)

37 lammation (CLNI) associated with an elevated aspartate transaminase (AST) level and portal tract feat

38 vealed that recipient age, serum creatinine, aspartate transaminase (AST) level, presence of edema, d

39 chemia/reperfusion (IR) injury with 24 hours aspartate transaminase (AST) levels >2000 IU/L (Group A)

40 HCV infection associated with elevated serum aspartate transaminase (AST) levels predicted the develo

41 n only a few weeks, and after 8 weeks, serum aspartate transaminase (AST) levels were doubled.

42 After 4 weeks, serum aspartate transaminase (AST) levels were elevated in eth

43 After reperfusion, serum aspartate transaminase (AST) levels were reduced up to 3

44 tion of gamma-glutamyl transferase (GGT) and aspartate transaminase (AST) provides signals for liver

45 iglycerides, alanine transaminase (ALT), and aspartate transaminase (AST) were measured.

46 iption polymerase chain reaction) as well as aspartate transaminase (AST), alanine transaminase (ALT)

47 r greater were associated with elevated ALT, aspartate transaminase (AST), and gamma-glutamyl transpe

48 e protein (CRP), alanine transaminase (ALT), aspartate transaminase (AST), and liver fat content.

49 liver enzymes, alanine transaminase (ALT) or aspartate transaminase (AST), are commonly used in clini

50 une hepatitis (AIH) by lower serum levels of aspartate transaminase (AST), gamma-globulin, and immuno

51 change from baseline was found in mean ALT, aspartate transaminase (AST), GGT, bilirubin, triglyceri

52 After 4 weeks, serum aspartate transaminase (AST), necrosis and inflammation

53 Peak transaminase (aspartate transaminase [AST] and alanine transaminase [A

54 markers of hepatic parenchymal injury (e.g., aspartate transaminase [AST], lactate dehydrogenase [LDH

55 epatic enzymes (alanine transferase, ALT and aspartate transaminase, AST) were only significantly obs

56 elevations in alanine amino transferase and aspartate transaminase at this dose level indicate that

57 ]/mg of creatinine, plasma homocysteine, and aspartate transaminase by more than 8-fold.

58 nor age, steatosis, cold ischemic time, peak aspartate transaminase, day 5 bilirubin or international

59 ents, infection in six (30%), and alanine or aspartate transaminase elevation in five (25%).

60 eumonia (13/10), and alanine transaminase or aspartate transaminase elevations (60/20).

61 ere it can be converted into oxaloacetate by aspartate transaminase (GOT1).

62 the ETC drives reversal of the mitochondrial aspartate transaminase (GOT2) as well as malate and succ

63 Plasma levels of TNF-alpha and aspartate transaminase in double-infected mice were grea

64 (32%), alanine transaminase increase (20%), aspartate transaminase increase (15%), anemia and thromb

65 ount, urea, bilirubin, alanine transaminase, aspartate transaminase, international normalized ratio,

66 k values of neutrophils, indirect bilirubin, aspartate transaminase, international normalized ratio,

67 iated with a significantly higher mean serum aspartate transaminase level (P =.

68 Time to significant fibrosis (defined as an aspartate transaminase level to platelet count ratio ind

69 Endpoints included peak serum aspartate transaminase level, postoperative complication

70 ry artery disease, congestive heart failure, aspartate transaminase level, upper age limits, and prio

71 on for 4 weeks significantly increased serum aspartate transaminase levels and hepatic pathology scor

72 Elevated serum aspartate transaminase levels confirmed that mortality w

73 Alanine transaminase and aspartate transaminase levels followed a sawtooth patter

74 Serum aspartate transaminase levels were elevated in ethanol-t

75 otoxicity (grade 3 or 4 change in alanine or aspartate transaminase levels) among 568 patients receiv

76 30.5), alanine aminotransferase levels, and aspartate transaminase levels.

77 ts, and had higher pre-ART triglycerides and aspartate transaminase levels.

78 t clamping (P = 0.015) significantly reduced aspartate transaminase levels.

79 DCD-NEVLP-groups showed significantly lower aspartate transaminase-levels compared with the SCS-grou

80 lanine transaminase (ALT), and mitochondrial aspartate transaminase (m-AST).

81 / degrees C increase (p = 0.005)], increased aspartate transaminase [OR, 2.47 (p = 0.019)], and decre

82 1), alanine aminotransferase (P = .024), and aspartate transaminase (P = .0040); elevated lactate deh

83 the serum levels of alanine transaminase and aspartate transaminase (p<0.05).

84 s generated from unlabeled glutamate via the aspartate transaminase reaction.

85 297 +/- 56, PUGNAc: 126 +/- 21 IU, p < .05), aspartate transaminase (sham surgery: 536 +/- 110, contr

86 including either end-stage liver disease or aspartate transaminase to platelet ratio index (APRI) of

87 sed the Enhanced Liver Fibrosis (ELF) score, aspartate transaminase-to-platelet ratio index (APRI) an

88 og creatinine, log alanine transaminase, log aspartate transaminase, UNOS status, donor gender, and w

89 Postoperative peak of aspartate transaminase was defined as primary endpoint,

90 Elevated alanine transaminase/aspartate transaminase was seen in 67% of patients (23%

91 nsient increases in alanine transaminase and aspartate transaminase were observed at Day 7, resolving